BMEA · Biomea Fusion, Inc.
$1.31
+0.03 (+2.34%)
At close · Jul 20
Going-concern doubt
— flagged May 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management believes that the existing financial resources are not sufficient to continue operating activities for at least twelve months past the issuance date of these unaudited condensed financial statements. The Company's ability to continue as a going concern will require the Company to raise additional capital to fund the Company's operations through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources. There can be no assurance that additional financing will be available to the Company or that such financing, if available, will be available on terms acceptable to the Company. Accordingly, there is substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed May 11, 2026
Market Cap
$94.71M
Shares
72.30M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.31
Open$1.28
Day$1.27–1.34
52W$0.87–2.99
Avg vol 30d945K
Short int13.8M · 19.1% float · 14.6d
Short vol36%
Last earningsMay 11, 2026
DataApr 2021–Jul 2026
Filing10-Q · May 11
Up next
Next earnings call
Oct 3, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 11, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Sell
Momentum
Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.7 · elevated
Equity put/call 0.66
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−6%
below
Price vs 50-day avg
−1%
below
RSI (14)
50
neutral
MACD trend
Negative
52-week position
21%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+11%
trailing
6-month return
+3%
trailing
YTD return
+6%
this year
Relative strength
−4%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
5 of 65 funds reported for Jun 30 · net +10.1K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
19.13% of float · ▼ -0.9% MoM · 14.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
65 holders — mid 3-yr range
Squeeze score
70
elevated · 0–100
Fundamentals
EPS growth
+69%
Y/Y
Free cash flow
$-70.7M
Balance sheet
$55.8M
net cash
Quant / Vol
risk profile
Volatility
90%
annualized · 1-yr
Max drawdown
−64%
past year
ATR
7.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−6%
Bearish
Price vs 50-day avg
−1%
Neutral
RSI (14)
50
Neutral
MACD trend
Negative
Bearish
52-week position
21%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
5 of 65 funds reported for Jun 30 · net +10.1K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
19.13% of float · ▼ -0.9% MoM · 14.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
65 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $1 · 21%
52-wk high $3
vs 200-day avg -6%
vs 50-day avg -1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BMEA
this stock
Biomea Fusion, Inc.
|
$94.71M | +5.6% | — | — | 19.1% |
|
ONC
BeOne Medicines Ltd.
|
$448.86B | +2.2% | +22179.2% | 913.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.95B | +6.0% | +46.2% | 28.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.47B | -12.8% | +20.8% | 16.4 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +0.6% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BMEA | -1.5% | +11.0% | +3.2% | -10.9% | +5.7% |
| SPY | -1.0% | -0.6% | +7.1% | -0.6% | +8.8% |
| vs SPY | -0.6% | +11.6% | -4.0% | -10.3% | -3.2% |